Results 121 to 130 of about 101,964 (348)

Dynamics of the CD9 interactome during bacterial infection of epithelial cells by proximity labelling proteomics

The FEBS Journal, EarlyView.
We describe the CD9 interactome in epithelial cells for the first time. The interactome is diverse and dynamic and changes dependent on infection with specific bacteria. We validate these data by showing functional interaction between CD9 with CD44 or CD147. We therefore demonstrate that CD9 is a universal organiser of bacterial adhesion platforms able
Paige A. Wolverson, Isabel Fernandes Parreira, Ruth H. Thompson, Mark O. Collins, Jonathan G. Shaw, Luke R. Green   +5 more
wiley   +1 more source

Multifocality and bilaterality in medullary thyroid cancer: basis for a proof-of-concept safety of lobectomy

European Thyroid Journal
Objective: At present, total thyroidectomy and central neck dissection are the surgical approaches recommended for the initial treatment of medullary thyroid cancer (MTC) independently of the size, number of tumor foci, age of patients, and other ...
Cappagli Virginia, Matrone Antonio, Bottici Valeria, Prete Alessandro, Ramone Teresa, Romei Cristina, Ciampi Raffaele, Ugolini Clara, Torregrossa Liborio, Piaggi Paolo, Elisei Rossella   +10 more
doaj   +1 more source

Renal effects of calcitonin and parathyroid extract in man [PDF]

, 1971
H. G. Haas, Maximilian A. Dambacher, Jan Gun aga, Thierry Lauffenburger   +3 more
openalex   +1 more source

Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case–control study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to examine the serum levels of vasoactive neuropeptides (calcitonin gene‐related peptide [CGRP], pituitary adenylate cyclase‐activating peptide‐38 [PACAP‐38], substance P [SP], and vasoactive intestinal peptide [VIP], which have been linked to the pathophysiology of migraine in adults) in pediatric ...
Sibğatullah Ali Orak, Muzaffer Polat, Mert Pak, Çisil Çerçi Kubur, Aslı Kübra Atasever, Celil Yilmaz, Fatma Taneli, Ahmet Angin, Beyhan Cengiz Özyurt   +8 more
wiley   +1 more source

Distribution of Calcitonin-Containing Cells in the Normal Neonatal Human Thyroid Gland: A Correlation of Morphology with Peptide Content [PDF]

, 1975
Hubert J. Wolfe, Ronald A. DeLellis, Edward F. Voelkel, Armen H. Tashjian   +3 more
openalex   +1 more source

Effectiveness and tolerability of liraglutide as add‐on treatment in patients with obesity and high‐frequency or chronic migraine: A prospective pilot study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess whether glucagon‐like‐peptide‐1 receptor (GLP‐1R) agonists could serve as a novel prophylactic treatment for migraine in patients with obesity. Background Increased intracranial pressure (ICP) is speculated to play a role in migraine mechanisms, as chronic migraine and idiopathic intracranial hypertension without ...
Simone Braca, Cinzia Valeria Russo, Antonio Stornaiuolo, Gennaro Cretella, Angelo Miele, Caterina Giannini, Roberto De Simone   +6 more
wiley   +1 more source

Renal Effects of Calcitonin [PDF]

, 1970
M. Cochran, Munro Peacock, George Sachs, B.E.C. Nordin   +3 more
openalex   +1 more source

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary: This randomized trial was designed to test the effectiveness and safety of rimegepant for the acute treatment of migraine among adults in Japan. Results indicated that rimegepant was more effective than placebo, and the 75 mg dose was observed to be more effective than the 25 mg dose.
Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +11 more
wiley   +1 more source

Secretion of immunoreactive calcitonin by human breast carcinomas. [PDF]

, 1975
R. Charles Coombes, G C Easty, Simone Detre, C. J. Hillyard, U. Stevens, Samia I. Girgis, L. Galante, L. H. Heywood, I. MacIntyre, Alan Nevill   +9 more
openalex   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source